Eli Lilly and Company

🇺🇸New York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Somewhat Bullish +50

Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?

📈 Eli Lilly (LLY) shares have risen roughly 6% over the past 30 days.

🎯 Leerink analyst David Risinger raised the price target to $1,232 with an Outperform rating on June 25.

🎯 Berenberg analyst Kerry Holford increased the price target to $1,135 while maintaining a Hold rating on June 22.

💊 Strong demand continues for metabolic treatments Mounjaro and Zepbound.

🤝 Eli Lilly completed the acquisition of Centessa Pharmaceuticals on June 24.

🧠 The acquired company focuses on orexin receptor 2 agonists for narcolepsy and sleep disorders.

📈 Stock price jumped approximately 1.5% immediately following the Centessa deal announcement.

🔬 The acquisition signals a strategic push into neuroscience and sleep medicine sectors.

Bullish Signals
  • LLY shares have gained roughly 6% over the past month, indicating positive market sentiment.
  • Analyst price targets were raised by both Leerink and Berenberg, reflecting confidence in the stock's valuation.
  • Strong consumer demand for metabolic treatments Mounjaro and Zepbound supports revenue growth expectations.
  • The successful completion of the Centessa Pharmaceuticals acquisition expands Lilly's portfolio into high-potential neuroscience areas.
Full Analysis
Eli Lilly and Company (NYSE: LLY) shares have appreciated by approximately 6% over the last month, driven by strong market demand for its metabolic treatments, Mounjaro and Zepbound. Analysts from Leerink and Berenberg recently raised their price targets to $1,232 and $1,135 respectively, citing positive momentum in the company's core therapeutic areas. On June 24, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, a clinical-stage firm specializing in medicines for narcolepsy and sleep-wake disorders. The deal marks a strategic expansion into neuroscience, focusing on orexin receptor 2 agonists to target wakefulness and alertness. Following the announcement, LLY stock gained an additional 1.5%. While the article highlights these positive developments and analyst upgrades, it concludes with a promotional pitch suggesting that certain AI stocks may offer superior short-term returns compared to LLY. The piece serves as a newsletter update rather than a deep-dive financial analysis of Lilly's long-term fundamentals.